Reinecke et al. demonstrated that Anakinra, an IL-1 receptor antagonist, inhibits pulmonary metastases in their preclinical model [61], so our clinical data linking plasma IL-1β levels with metastasis and EFS (wherein metastasis is the predominant event), in the context of the mechanistic studies published by other groups, provide strong justification for clinical trials of IL-1 inhibition to prevent metastasis in patients with osteosarcoma. This evidence concerns the gene IL1A and osteosarcoma.